THE FREQUENCY OF EGFR AND KRAS MUTATIONS IN THE
TURKISH POPULATION WITH NON-SMALL CELL LUNG
CANCER AND THEIR RESPONSE TO ERLOTINIB THERAPY
Demiray A, Yaren A, Karagenç N, Bir F, Demiray AG,
Karagür ER, Tokgün O, Elmas L, Akça H, https://orcid.org/0000-0002-3343-0184.
*Corresponding Author: Professor Dr. Hakan Akça, Cancer Research Center, Pamukkale University,
11 University Street, Denizli Turkey. E-mail: hakca@pau.edu.tr (primary), hakanakca@yahoo.com
page: 21
download article in pdf format
|
|
Abstract
In this study, profiles of epidermal growth factor receptor
(EGFR) and Kirsten ras sarcoma (KRAS) mutations
and response to erlotinib therapy have been investigated in
patients with non-small cell lung cancer (NSCLC). DNA
from 300 patients with NSCLC was extracted from paraf-finembedded
tissues. After the extracted DNA was sequenced
by pyrosequencing method, a total of 97 (32.0%) patients
out of 300 were detected to carry an EGFR mutation and 75
(25.0%) patients out of 300 carried a KRAS mutation; 20
(6.6%) patients were detected to carry both of EGFR and
KRAS mutations. The EGFR mutations were found to be
statistically significant in female patients (48.0 women vs.
28.0% men, non smokers (49.0 vs. 26.0%) and adenocarcinoma
(37.8 vs. squamous 26.8%). The overall rate of survival
in patients receiving erlotinib therapy than in patients who did
not. In patients without the KRAS mutation, the median overall
survival rate was 161 ± 30 weeks with erlotinib therapy
and 90 ± 13 weeks in patients without erlotinib therapy. In
patients having KRAS mutation, the median overall survival
was 98 ± 16 weeks with erlotinib therapy and 34 ± 16 weeks
with no erlotinib therapy. In our study, we once again demonstrated
that the presence of these mutations affected response
to erlotinib therapy. The KRAS mutations negatively affected
survival rate with and without erlotinib therapy.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
